19 Lopes G, Wu YL, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as f irst-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥1%: open-label, ...
Background KEYNOTE-048 (NCT02358031) is a randomized, open-label, phase 3 trial of pembrolizumab (pembro) or pembro + chemotherapy (chemo) vs EXTREME (E) as first-line therapy for recurrent and/or metastatic (R/M) head and neck squamous ... N Ngamphaiboon,K Tanaka,RL Hong,... - ...
摘要号:4003 帕博利珠单抗(pembro)联合吉西他滨和顺铂(gem/cis)vs.安慰剂联合gem/cis 治疗晚期胆道恶性肿瘤(BTC):3期KEYNOTE-966研究的健康相关生活质量 (HRQoL)分析 Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/...
19 Lopes G, Wu YL, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as f irst-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS)≥1%: open-label, phase 3 KEYNOTE-042 study. J Clin Oncol, 2018, 36(18 suppl): LBA4...